THE KOREA ECONOMIC DAILY, GLOBAL EDITION

South Korean bio-health company HK inno.N announced on Monday that it has released the new drug K-CAB for gastroesophageal reflux disease (GERD) in Singapore and held a commemorative symposium for local medical professionals.

With this launch, K-CAB has now been introduced in Singapore, following China, Mongolia, the Philippines, Mexico, and Indonesia.

K-CAB is a P-CAB (potassium-competitive acid blocker) class medication for treating GERD and has received approval as a 30th domestically developed new drug.

Local distribution is managed by United Italian Trading Corporation (UITC), a pharmaceutical marketing distribution company in Singapore. HK inno.N exports the finished product to UITC, which then handles local sales and marketing.

"The average annual growth rate of the pharmaceutical market in Singapore over the past three years has been 11%, making it one of the standout growth countries among major Southeast Asian nations," CEO of HK inno.N Kwak Dalwon said. "We will continue to collaborate closely with our local partners to ensure the successful overseas approval and launch of K-CAB."

Write to Ji-Hyun Lee at bluesky@hankyung.com